Drug–Drug Interactions of Newly Approved Direct|Acting Antiviral

Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral ...

Hepatitis C is a major health problem worldwide, frequently resulting in cirrhosis and increasing the risk of hepatocellular carcinoma ...

Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral ...

This review summarizes researches of DDIs focusing on newly approved DAAs (elbasvir, grazoprevir, velpatasvir, voxilaprevir, glecaprevir, pibrentasvir)

Managing drug–drug interactions with new direct‐acting antiviral ...

DDI are more likely to occur with 3D regimen, daclatasvir, simeprevir and ledipasvir, as they are all both substrates and inhibitors of P-gp and ...

Drug-Drug Interactions Potential of Direct-Acting Antivirals for the ...

Highlights · Direct-acting antivirals present a major potential for drug-drug interactions. · Drug-drug interaction potential is highly variable between direct- ...

Review of Clinically Relevant Drug Interactions with Next ...

Numerous clinically relevant drug-drug interactions (DDIs) were identified with the newer generation DAAs and commonly prescribed drugs. NS3/4A ...

(PDF) Drug–Drug Interactions of Newly Approved Direct-Acting ...

The newly approved DAA regimens may be prescribed with other drugs simultaneously, increasing the potential of pharmacokinetic interactions. Therefore, the ...

Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral ...

Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C ; Nov 2023, 5,941, 1,529 ; Dec 2023, 6,054, 1,640 ; Jan 2024 ...

Drug–Drug Interactions With Novel All Oral Interferon-Free Antiviral ...

Background. With the approval of direct-acting antivirals (DAAs), the management of drug–drug interactions (DDIs) has become an important challenge while ...

Prevalence of Potential Drug Interactions With Direct-Acting ...

COVID-19 direct-acting antivirals could have potential drug-drug interactions (DDI). •. Higher prevalence of potential DDIs in older patients ...

Frequency of Potential Drug–Drug Interactions in the Changing ...

With the introduction of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, drug–drug interactions (DDIs) emerged as ...

Therapy interruptions and drug interactions during acute ...

Therapy interruptions and drug interactions during acute hospitalization in patients taking direct acting antivirals for chronic hepatitis C ...

Drug-drug interactions between direct-acting antivirals and

As the first line of treatment for hepatitis C virus (HCV) infection, direct-acting antivirals (DAAs) have greater efficacy and fewer adverse effects than other ...

Drug-Drug Interactions With Antiviral Agents in People Who Inject ...

Potential drug-drug interactions in the area of HIV/hepatitis C virus (HCV) coinfection and injection drug use, including those between antiretrovirals ...

Direct-Acting Antivirals (DAAs): Drug-Drug Interactions (DDIs) in the ...

Direct antiviral agents (DAAs) improved tolerability and efficacy for HCV-infected patients, but drug-drug interactions (DDIs) have the ...

(PDF) Drug-Drug Interactions In The Era of Direct-Acting Antivirals ...

PDF | On Oct 1, 2018, Marcel de Souza Nogueira and others published Drug-Drug Interactions In The Era of Direct-Acting Antivirals and Clinical Outcomes of ...

Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and ...

The drug interactions that are of clinical significance are anticonvulsants, statins, macrolide antibiotics, triazole antifungals, digoxin, ...

Drug–Drug Interactions between Direct Oral Anticoagulants and ...

Hepatitis C direct-acting antiviral agents (DAAs), via P-glycoprotein or CYP3A4 inhibition, may increase DOAC exposure with relevant bleeding risk.

Management of drug interactions with direct‐acting antivirals in ...

Direct-acting antivirals (DAAs) for treatment of chronic hepatitis C virus (HCV) infection can cause drug–drug interactions (DDIs) with ...

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting ...

Cobicistat-boosted elvitegravir, when used with tenofovir disoproxil fumarate, should not be combined with ledipasvir as this can potentially raise tenofovir ...

Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir

To assess drug-drug interaction (DDI) potential for the three direct-acting antiviral (3D) regimen of ombitasvir, dasabuvir, and paritaprevir, in vitro studies